Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma

Marek Trněný • 12 Jun 2015
EHA 2015
Mantle Cell Lymphoma Lenalidomide

Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Association (EHA). This results showed that lenalidomide, an immunomodulator, provided clinically significant improved activity irrespective of baseline demographics or disease characteristics when compared with investigator’s choice in patients with relapsed or refractory mantle cell lymphoma.

More from Marek Trněný

The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
2:37
The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
Marek Trněný • 12 Jun 2026
Bringing epcoritamab into earlier lines of therapy for DLBCL
1:24
Bringing epcoritamab into earlier lines of therapy for DLBCL
Marek Trněný • 5 Sep 2025
Rates of peripheral neuropathy observed in the POLARIX trial
1:31
Rates of peripheral neuropathy observed in the POLARIX trial
Marek Trněný • 5 Sep 2025
EPCORE NHL-2: epcoritamab + intensive chemotherapy in patients with R/R DLBCL eligible for autoSCT
3:56
EPCORE NHL-2: epcoritamab + intensive chemotherapy in patients with R/R DLBCL eligible for autoSCT
Marek Trněný • 5 Sep 2025

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals